A Phase 1 interventional study of nacubactam and meropenem in Gram-negative Bacterial Infections, sponsored by Hoffmann-La Roche. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-23.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Gram-Negative Bacterial Infections with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Gram-Negative Bacterial Infections · United States.
Among the 23 studies in Gram-Negative Bacterial Infections with a site in United States, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2017, is one of 2 in phase 1, and was the 9th registered.
58 studies on the registry are indexed under Gram-Negative Bacterial Infections; 10 are open to participants now.
Browse Gram-Negative Bacterial Infections studies →3 of the 23 studies in Gram-Negative Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:
University of Tennessee · Sites in United States
Ages 18–80
Pfizer · Sites in United States, Argentina, Bulgaria and 6 more countries
Ages up to 39 wk
Pfizer · Sites in United States, China, Greece and 5 more countries
Ages 9 mo–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Gram-Negative Bacterial Infections studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 2 · Phase 4 3
First in 2005; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 70 across 43 interventional studies indexed under Gram-Negative Bacterial Infections.
Median enrollment 48 across the 16 interventional studies, 197 across the 7 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 1 study filed under Gram-Negative Bacterial Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in Gram-Negative Bacterial Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07465432University of TennesseePharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries | 2027-02-28 |
| NCT05639647PfizerStudy of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections | 2027-03-31 |
| NCT06462235PfizerA Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) | 2027-04-25 |
| NCT07562087Tarsus Pharmaceuticals, Inc.A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 23 studies in Gram-Negative Bacterial Infections with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the intrapulmonary penetration of nacubactam in healthy volunteers. Nacubactam is a novel non-beta-lactam beta-lactamase inhibitor being developed as a combination therapy with the beta-lactam meropenem for the treatment of serious gram-negative bacterial infections. Adult male and female healthy participants will receive a single intravenous infusion of nacubactam co-administered with meropenem and then undergo a bronchoalveolar lavage (BAL) procedure to collect lung epithelial lining fluid (ELF) for measurement of intrapulmonary concentrations of nacubactam and meropenem.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of nacubactam co-administered with meropenem.
Drug: nacubactam · Drug: meropenem
Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.
Also known as: RO7079901
Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.
Also known as: Merrem
Epithelial Lining Fluid (ELF) Concentration of Nacubactam to Plasma Concentration of Nacubactam Ratio
The ELF to plasma ratio will be calculated from the concentration of nacubactam in ELF and plasma as a measure of the intrapulmonary penetration of nacubactam in healthy participants.
Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration
ELF Concentration of Meropenem to Plasma Concentration of Meropenem Ratio
The ELF to plasma ratio will be calculated from the concentration of meropenem in ELF and plasma as a measure of the intrapulmonary penetration of meropenem in healthy participants..
Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration
Area Under the Plasma Concentration-Time Curve from time 0 to 8 hours (AUC0-8) of Nacubactam in ELF
Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration
Maximum Concentration (Cmax) of Nacubactam in ELF
Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration
Area Under the Plasma Concentration-Time Curve from Time 0 to 8 Hours (AUC0-8) of Nacubactam in Blood Plasma
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Maximum Concentration (Cmax) of Nacubactam in Blood Plasma
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Time to Reach the Maximum Plasma Concentration (Tmax) of Nacubactam
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Clearance (CL) of Nacubactam
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Volume of Distribution of the Central Compartment (Vc) of Nacubactam
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Volume of Distribution at Steady-State (Vss) of Nacubactam
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Area Under the Plasma Concentration-Time Curve from Time 0 to 8 Hours (AUC0-8) of Meropenem in ELF
Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration
Maximum Concentration (Cmax) of Meropenem in ELF
Time frame: At 2, 3, 4, 6 and 8 hours after study drug administration
Area Under the Plasma Concentration-Time Curve from Time 0 to 8 hours (AUC0-8) of Meropenem in Blood Plasma
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Maximum Concentration (Cmax) of Meropenem in Blood Plasma
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Time to Reach the Maximum Plasma Concentration (Tmax) of Meropenem
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Clearance (CL) of Meropenem
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Volume of Distribution of the Central Compartment (Vc) of Meropenem
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Volume of Distribution at Steady-State (Vss) of Meropenem
Time frame: At 0, 0.75, 1.5, 2, 3, 4, 6 and 8 hours after study drug administration
Number of Participants with Adverse Events
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: From baseline up to 14 days after study drug administration
Ran from Jun 2017 to primary completion in Aug 2017, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nacubactam
Gram-Negative Bacterial Infections →